- Home
- RNP vs MESO Comparison
RNP vs MESO Comparison
Compare RNP & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNP
- MESO
- Stock Information
- Founded
- RNP 2003
- MESO 2004
- Country
- RNP United States
- MESO Australia
- Employees
- RNP N/A
- MESO N/A
- Industry
- RNP Investment Managers
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNP Finance
- MESO Health Care
- Exchange
- RNP Nasdaq
- MESO Nasdaq
- Market Cap
- RNP 1.0B
- MESO 1.2B
- IPO Year
- RNP N/A
- MESO N/A
- Fundamental
- Price
- RNP $21.02
- MESO $14.63
- Analyst Decision
- RNP
- MESO Strong Buy
- Analyst Count
- RNP 0
- MESO 4
- Target Price
- RNP N/A
- MESO $13.50
- AVG Volume (30 Days)
- RNP 117.6K
- MESO 552.8K
- Earning Date
- RNP 01-01-0001
- MESO 08-28-2024
- Dividend Yield
- RNP 7.94%
- MESO N/A
- EPS Growth
- RNP N/A
- MESO N/A
- EPS
- RNP N/A
- MESO N/A
- Revenue
- RNP N/A
- MESO $5,902,000.00
- Revenue This Year
- RNP N/A
- MESO $66.05
- Revenue Next Year
- RNP N/A
- MESO $348.27
- P/E Ratio
- RNP N/A
- MESO N/A
- Revenue Growth
- RNP N/A
- MESO N/A
- 52 Week Low
- RNP $15.52
- MESO $1.61
- 52 Week High
- RNP $21.27
- MESO $19.15
- Technical
- Relative Strength Index (RSI)
- RNP 30.18
- MESO 64.37
- Support Level
- RNP $20.65
- MESO $12.20
- Resistance Level
- RNP $22.17
- MESO $19.15
- Average True Range (ATR)
- RNP 0.40
- MESO 0.98
- MACD
- RNP -0.17
- MESO 0.37
- Stochastic Oscillator
- RNP 14.86
- MESO 48.93
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.